Tesla has announced the Powerwall 3P, a new variant of its home battery with a native three-phase inverter built into a single unit. The product, announced for the German market first, eliminates the ...

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...

Blue Origin’s New Glenn rocket at liftoff during the NG-2 mission on Nov. 13. Credit: Blue Origin The U.S. Space Force is now taking proposals from new launch providers with rockets ready to fly by ...

Nothing is more confusing in the tech world than USB. First, there's understanding every USB port symbol and icon. Some USB ports are orange and some USB ports have lightning bolts. That's before we ...

(RTTNews) - Shares of SELLAS Life Sciences Group Inc. (SLS) are up nearly 7% at $1.86 in premarket trading, following promising clinical data from its ongoing Phase 2 study of SLS009 in ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...

CUYAHOGA FALLS, Ohio (WJW) — A beloved costume shop in Northeast Ohio has announced the closing of its brick-and-mortar location this year. After nearly 60 years in business, Mr. Fun’s Costumes and ...

Add Yahoo as a preferred source to see more of our stories on Google. For more than half a century, it’s been a place where make-believe met Main Street, where curiosity, costumes and community all ...

The cheerful Mr. Fun Computer is gone, replaced by a digital ghost corrupted by a virus from Black. Now he's infecting everything—spreading sorrow, erasing joy, and enslaving his former allies. With ...

PARIS — Interim data from two pivotal phase 3 trials, STOP-HS1 and STOP-HS2, further support the JAK inhibitor povorcitinib as a potential treatment for moderate-to-severe hidradenitis suppurativa (HS ...